Earnings summaries and quarterly performance for 4D Molecular Therapeutics.
Executive leadership at 4D Molecular Therapeutics.
Board of directors at 4D Molecular Therapeutics.
Research analysts covering 4D Molecular Therapeutics.
Recent press releases and 8-K filings for FDMT.
4D Molecular Therapeutics, Inc. Issues Pre-Funded Warrants
FDMT
- 4D Molecular Therapeutics, Inc. (FDMT) entered into exchange agreements on January 22, 2026, with RA Capital Healthcare Fund, L.P. and Biotechnology Value Fund, L.P. and its affiliates (BVF).
- RA Capital exchanged 4,850,000 shares of common stock for a pre-funded warrant to acquire an equal number of shares, and BVF exchanged 1,750,000 shares of common stock for a pre-funded warrant to acquire 1,750,000 shares.
- These pre-funded warrants have an exercise price of $0.0001 per underlying share, are immediately exercisable, and do not expire until fully exercised.
- As of January 23, 2026, the company had 51,007,874 shares outstanding, not including 16,935,665 shares issuable upon exercise of the outstanding pre-funded warrants.
- The warrants include a beneficial ownership blocker, preventing holders from exceeding 4.99% or 9.99% of the total outstanding common stock upon exercise.
Jan 26, 2026, 9:05 PM
4D Molecular Therapeutics Provides Update on 4D-150 Clinical Development and Financial Position
FDMT
New Projects/Investments
M&A
Guidance Update
- 4D Molecular Therapeutics' lead product candidate, 4D-150, is advancing with two ongoing Phase 3 studies for wet AMD, 4FRONT-1 and 4FRONT-2, and a Phase 3 study for DME is planned to initiate in Q3 2026.
- Enrollment for the 4FRONT-1 wet AMD Phase 3 study has exceeded 400 patients as of January 14, 2026, with completion expected in Q1 2026 and top-line data anticipated in H1 2027.
- The company reported a strong financial position with approximately $514 million in cash and cash equivalents at the end of 2025, providing a cash runway into the second half of 2028.
- 4D Molecular Therapeutics secured a partnership with Otsuka for Asia-Pacific rights for 4D-150, which included an $85 million upfront payment and an estimated $50 million in cost coverage.
Jan 14, 2026, 3:30 PM
4D Molecular Therapeutics Provides Update on 4D-150 Clinical Development and Financial Position
FDMT
Board Change
Guidance Update
New Projects/Investments
- 4D Molecular Therapeutics is advancing 4D-150, its lead product candidate for wet AMD and DME, with two Phase 3 studies for wet AMD (4FRONT-1 and 4FRONT-2) expected to complete enrollment in Q1 2026 and Q2 2026, respectively. Top-line data for 4FRONT-1 is anticipated in H1 2027.
- For DME, the company has regulatory alignment for a single Phase 3 study, which is expected to initiate in Q3 2026.
- The company reported a strong financial position with approximately $514 million in cash and cash equivalents at the end of 2025, providing a cash runway into the second half of 2028. This includes a $100 million raise in Q4 2025.
- The anti-VEGF therapy market, which 4D-150 targets, is approximately $17 billion annually, with $14 billion specifically for wet AMD and DME.
- A partnership with Otsuka for Asia-Pacific rights for 4D-150 generated $85 million upfront and an estimated $50 million in cost coverage.
Jan 14, 2026, 3:30 PM
4D Molecular Therapeutics Highlights 4D-150's Potential in Retinal Care
FDMT
New Projects/Investments
Product Launch
- 4D Molecular Therapeutics presented its 4D-150 program, a gene therapy designed for Wet AMD and Diabetic Macular Edema (DME), targeting a $14B+ global market by 2025.
- 4D-150 demonstrates potential for paradigm-shifting durability, with Phase 2b data showing 73% of Wet AMD patients injection-free at 1.5 years in a Phase 3 comparable population, and Phase 1/2 data showing 44% of DME patients injection-free at 60 weeks.
- The company is advancing global Phase 3 programs for both Wet AMD and DME, with key milestones including randomization completion for Wet AMD trials (4FRONT-1 and 4FRONT-2) in Q1 2026 and H2 2026, respectively, and topline data expected in H1 2027 and H2 2027.
- 4D Molecular Therapeutics reported $514 million in cash at year-end 2025, providing a financial runway expected into H2 2028.
Jan 14, 2026, 3:30 PM
4D Molecular Therapeutics Provides Update on 4D-150 Clinical Progress and Financial Position
FDMT
New Projects/Investments
Guidance Update
M&A
- 4D Molecular Therapeutics (FDMT) is developing 4D-150, a gene therapy for wet AMD and DME, designed to provide durable, lifelong anti-VEGF therapy and reduce the need for frequent injections, with strong Phase 1/2/2b safety and durability data.
- Enrollment for the 4FRONT-1 Phase 3 study (wet AMD) has exceeded expectations, with over 400 patients enrolled as of the document date, and is expected to complete in Q1 2026. Enrollment for 4FRONT-2 (wet AMD) is expected to complete in H2 2026.
- The company has achieved FDA and EMA alignment for a single Phase 3 study for 4D-150 in DME, with initiation planned for Q3 2026.
- FDMT ended 2025 with $514 million in cash and cash equivalents, providing a runway into H2 2028, and has a partnership with Otsuka for Asia-Pacific rights, which included an $85 million upfront payment and an estimated $50 million in cost coverage.
- Key upcoming catalysts include 4FRONT-1 enrollment completion in Q1 2026, 4FRONT-2 enrollment completion in Q2 2026, DME Phase 3 initiation in Q3 2026, and 4FRONT-1 top-line data in H1 2027.
Jan 14, 2026, 3:30 PM
FDMT Provides Update on 4D-710 Gene Therapy for Cystic Fibrosis
FDMT
New Projects/Investments
Guidance Update
- FDMT's 4D-710 gene therapy for Cystic Fibrosis (CF) demonstrated durable CFTR expression in the lung for one year or more at the 2.5 x 10^14 vector genomes dose, with expression levels remaining within the target therapeutic range at one to three years.
- The Phase 1 trial for 4D-710 showed excellent safety and tolerability for lower doses (2.5 x 10^14 and 5 x 10^14 vector genomes), with adverse events commonly associated with nebulized therapies resolving quickly.
- Clinical activity at the 2.5 x 10^14 dose (selected for Phase 2) included meaningful improvements in Lung Clearance Index (LCI) and Cystic Fibrosis Quality of Life (CFQR) respiratory domain scores across multiple time points, and consistent FEV1 response in some participants.
- The program is fully funded by the Cystic Fibrosis Foundation into the second half of 2026, with Phase 2 enrollment expected to be completed in the first half of 2026.
- Regulatory discussions with the FDA are ongoing, with LCI emerging as a useful and increasingly accepted primary efficacy endpoint for CF studies, particularly in pediatrics and becoming more open for adults.
Dec 17, 2025, 1:00 PM
4D Molecular Therapeutics Provides Update on 4D-710 Gene Therapy for Cystic Fibrosis
FDMT
New Projects/Investments
Guidance Update
- 4D Molecular Therapeutics (FDMT) is developing 4D-710, an AAV gene therapy for cystic fibrosis (CF) lung disease, which is administered via an FDA-approved nebulizer using their novel A101 vector.
- The Phase 1 trial focused on dose finding, safety, and CFTR expression levels. The 2.5 x 10^14 vector genomes dose was selected for Phase 2 due to greater improvements observed compared to the 5 x 10^14 vector genomes dose. A higher dose of 2 x 10^15 vector genomes was discontinued due to high transgene expression in non-target tissues and one related serious adverse event.
- First-time data from the Phase 1 trial demonstrated durable CFTR expression in the lung for one year or more, with persistent expression levels in airway epithelial cells observed at one to three years post-dosing, even at the lowest Phase 2 dose.
- FDMT is on track to complete Phase 2 enrollment in the first half of 2026 and plans to share a comprehensive program update in the second half of 2026. The company is also developing a redosing strategy, anticipating a 12- to 18-month window, and will leverage the REACH study as an external control group for Phase 3.
Dec 17, 2025, 1:00 PM
FDMT Provides Positive Phase I Data and Phase II Update for 4D-710 Cystic Fibrosis Gene Therapy
FDMT
New Projects/Investments
Product Launch
- FDMT's 4D-710 gene therapy for cystic fibrosis lung disease demonstrated clinically meaningful lung function activity improvements and was well tolerated through one year of follow-up in Phase I.
- CFTR expression with 4D-710 was robust at one month and persisted for at least one year, remaining within or above the target therapeutic range.
- Phase II enrollment is currently underway for 4D-710, utilizing the 2.5 E14 vector genomes dose level, which showed greater improvements in Phase I compared to higher doses.
- The 4D-710 program is fully funded by the Cystic Fibrosis Foundation into the second half of 2026, with redosing expected to be feasible and efficient, potentially every 12-18 months.
Dec 17, 2025, 1:00 PM
4DMT provides update on 4D-710 cystic fibrosis gene therapy program
FDMT
New Projects/Investments
- 4D-710, a gene therapy for cystic fibrosis, demonstrated positive Phase I results, showing good tolerability and clinically meaningful improvements in lung function (FEV1, LCI) and quality of life (CFQ-R) over one year.
- The therapy achieved durable CFTR expression in lung biopsies for at least one year, and up to three years, even at the lowest Phase II dose of 2.5 E14 vector genomes.
- Phase II enrollment for 4D-710 is underway at the 2.5 E14 vector genomes dose and is projected to conclude in the first half of 2026.
- The program is fully funded by the Cystic Fibrosis Foundation into the second half of 2026, with a comprehensive program update anticipated in the second half of 2026.
- The company is actively engaging with the FDA regarding redosing strategies and the increasing acceptance of Lung Clearance Index (LCI) as a primary efficacy endpoint for regulatory approval.
Dec 17, 2025, 1:00 PM
FDMT Reports Positive 4D-710 Phase I Results and Phase II Advancement
FDMT
New Projects/Investments
Product Launch
- 4D-710 for cystic fibrosis lung disease demonstrated clinically meaningful lung function and respiratory-related improvements through one year of follow-up, and robust, durable CFTR expression for at least one year, even at the lowest dose. The 2.5 E14 vector genomes dose was selected for Phase II.
- Phase II enrollment for 4D-710 is now underway with the selected dose, and the program is fully funded by the Cystic Fibrosis Foundation into the second half of 2026.
- Paired biopsy data showed durable transgene expression after a single dose for one to three years, validating the AAV platform. A comprehensive program update is planned for the second half of 2026, with potential discussions for accelerated approval with the FDA.
Dec 17, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more